NTCT-05EFFICACY AND SAFETY ASSESSMENT OF THE USE OF BEVACIZUMAB AND TEMOZOLOMIDE PLUS RADIOTHERAPY IN PATIENTS WITH RECENTLY DIAGNOSED GLIOBLASTOMA, A SINGLE INSTITUTION EXPERIENCE.

In the present study, we report on the safety and efficacy of bevacizumab and temozolomide plus radiotherapy for recently diagnosed GBM patients after surgical resection (either partial or near total). METHODS: Five consecutive patients diagnosed with GBM who presented to our institution after primary surgical resection, underwent a first line of therapeutics protocol, a combination of bevacizumab (10 mgs/kg) and temozolamide (75mgs/ m2) for 6 weeks, until progression, toxicity or death. Assessments were performed every two weeks and the primary end points were therapeutic safety and efficacy, tolerance as evaluated by clinico-radiological response as well the Common Terminology Criteria Adverse Events (CTCAE v5.0) and WHO Performance Status. RESULTS: From the five patients included on the study 3 women and 2 men, median age 55, 2 patients present grade I proteinuria, 2 patients present with hypertension grade I and II the last one requiring treatment and follow up by cardiology None of them required discontinuation of the treatment, all of them showed remission during the follow up. CONCLUSIONS: The results of the current study shows that bevacizumab and temozolamide plus radiotherapy as a front line therapy is safe and effective in treating patients with recently diagnosed GBM.